Trials / Recruiting
RecruitingNCT07249905
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- ModeX Therapeutics, An OPKO Health Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
Conditions
- Lymphoma
- Waldenström Macroglobulinemia (WM)
- DLBCL - Diffuse Large B Cell Lymphoma
- PMBCL
- HGBCL
- FL Lymphoma
- Lymphoplasmacytic Lymphoma
- Follicular Lymphoma (FL)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MDX2003 | MDX2003 intravenous infusion |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2028-01-01
- Completion
- 2030-04-01
- First posted
- 2025-11-25
- Last updated
- 2026-03-03
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT07249905. Inclusion in this directory is not an endorsement.